Triamcinolone Hexacetonide

CHEMBL1200878 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

532.6 g/mol

LogP

4.8

Phase

4

A hexacetonide form of triamcinolone with the same therapeutic properties. This corticosteroid medication reduces inflammation and immune activity and is used to treat a wide range of conditions including asthma, allergic reactions, skin conditions like eczema and psoriasis, and joint inflammation from arthritis.

Masse moléculaire

532,6000 g/mol

LogP

4,80

TPSA

99,10 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Pancreatic Cancer Glaucoma Age-Related Macular Degeneration Pain Management Rheumatoid Arthritis Asthma Chronic Obstructive Pulmonary Disease Migraine Melanoma Psoriasis Systemic Lupus Erythematosus Stroke Lymphoma Rheumatology Type 2 Diabetes Hypertension Breast Cancer Atopic Dermatitis Gout Chronic Pain Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC(C)(C)CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C

InChI

InChI=1S/C30H41FO7/c1-25(2,3)15-24(35)36-16-22(34)30-23(37-26(4,5)38-30)13-20-19-9-8-17-12-18(32)10-11-27(17,6)29(19,31)21(33)14-28(20,30)7/h10-12,19-21,23,33H,8-9,13-16H2,1-7H3/t19-,20-,21-,23+,27-,28-,29-,30+/m0/s1

Molecular Formula

C30H41FO7

HBD / HBA

1 / 8

Liaisons Rotatives

6

Atomes Lourds

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A hexacetonide form of triamcinolone with the same therapeutic properties. This corticosteroid medication reduces inflammation and immune activity and is used to treat a wide range of conditions including asthma, allergic reactions, skin conditions like eczema and psoriasis, and joint inflammation from arthritis.

Yes, Triamcinolone Hexacetonide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200878. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 21826. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Triamcinolone Hexacetonide sur PillFYI

Structure

Données Clés

Formule: C30H41FO7
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.